Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: main results from the Rosiglitazone Atherosclerosis Study.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Blackwell Scientific Publications Country of Publication: England NLM ID: 8904841 Publication Model: Print Cited Medium: Print ISSN: 0954-6820 (Print) Linking ISSN: 09546820 NLM ISO Abbreviation: J Intern Med Subsets: MEDLINE
    • Publication Information:
      Original Publication: Oxford : Blackwell Scientific Publications, c1989-
    • Subject Terms:
      Insulin Resistance*; Atherosclerosis/*drug therapy ; Carotid Artery Diseases/*drug therapy ; Diabetes Mellitus, Type 2/*drug therapy ; Diabetic Angiopathies/*drug therapy ; Hypoglycemic Agents/*therapeutic use ; Thiazolidinediones/*therapeutic use; Adult ; Aged ; Aged, 80 and over ; Carotid Artery Diseases/pathology ; Cohort Studies ; Diabetes Mellitus, Type 2/pathology ; Diabetic Angiopathies/pathology ; Disease Progression ; Double-Blind Method ; Female ; Humans ; Male ; Middle Aged ; Rosiglitazone ; Sweden ; Tunica Intima/pathology
    • Abstract:
      Objective: Insulin resistance is associated with progression of atherosclerosis. We assessed the effect of 12 months of treatment with rosiglitazone (RSG) on the progression of carotid intima-media thickness (IMT) in people with type 2 diabetes mellitus (T2DM) or the insulin resistance syndrome (IRS).
      Design: Randomized, double-blind, placebo-controlled trial.
      Setting: Malmö University Hospital, Malmö, Sweden.
      Subjects: 555 subjects (200 with T2DM and 355 nondiabetics with IRS according to EGIR criteria), aged 35-80 years. 447 subjects (165 T2DM and 282 IRS) completed the study.
      Intervention: Participants were allocated to placebo or RSG 4 mg for 2 months and then 8 mg daily.
      Main Outcome Measure: Change in composite IMT [mean IMT in the common carotid artery (CCA) and maximal IMT in the bulb] was the primary and various other IMT measures were secondary outcome variables.
      Results: There was no effect of RSG treatment in the mixed population. In T2DM patients there was a reduced progression of the composite IMT (mean change: 0.041 vs. 0.070 mm, P = 0.07), and of the mean IMT CCA (mean change: -0.005 mm vs. 0.021 mm, P = 0.007). RSG treatment led to significant reductions of HOMA-IR, fasting plasma glucose, HbA1c, PAI-1 activity, fibrinogen, C-reactive protein and matrix metalloproteinase-9.
      Conclusions: In a mixed study population of patients with T2DM and IRS RSG treatment was not associated with a statistically significant reduction of carotid IMT progression rate. Separate analyses of these two patient groups indicated, however, a significant beneficial effect on CCA IMT in T2DM patients but no similar effect in subjects with IRS.
    • Accession Number:
      0 (Hypoglycemic Agents)
      0 (Thiazolidinediones)
      05V02F2KDG (Rosiglitazone)
    • Publication Date:
      Date Created: 20070220 Date Completed: 20070423 Latest Revision: 20181201
    • Publication Date:
      20231215
    • Accession Number:
      10.1111/j.1365-2796.2007.01767.x
    • Accession Number:
      17305652